You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Guidelines & Advice

About Guidelines Email Guidelines Team

Displaying Guidelines

15 Items

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Document Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

Endorsement of the 2018 American Society of Clinical Oncology Treatment of Malignant Pleural Mesothelioma Guideline

Document Status: In-Review
ID: 7-14
Version: 3

Dec 2018

First-line treatment of advanced-stage Hodgkin lymphoma

Document Status: Current
ID: ES 6-25

Oct 2024

Follow-Up Model of Care for Cancer Survivors: Recommendations for the Delivery of Follow-up Care for Cancer Survivors in Ontario

Document Status: Current
ID: N/A
Version: N/A

Mar 2019

Ibritumomab Tiuxetan in Lymphoma

Document Status: Archived
ID: 6-17

Nov 2013

Iodine-131 Tositumomab in Lymphoma

Document Status: Archived
ID: 6-19

Jan 2007

Oncology Caregiver Support Framework

Document Status: Current
ID: N/A
Version: N/A

Oct 2019

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Document Status: Current
ID: GL-END 3-25

Nov 2023

Organizational Guidance for the Care of Patients with Central Nervous System Tumours in Ontario: Consensus Recommendations

Document Status: Current
ID: GL 9-11

Oct 2024

Position Statements for Nursing Practice in Cancer Care

Document Status: Current
Version: 2

May 2021

Radionuclide Therapy for Neuroendocrine Malignancies

Document Status: Current
ID: 12-13

Aug 2011

Radionuclide Therapy for Patients with Neuroendocrine Tumors (NETs) in Ontario: Expert Panel Report

Document Status: Current
ID: GL-C50-01

Jan 2011